Search - tctmd.com

Displaying 21 - 40 of 108

Sort: Relevancy | Date

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

Caitlin E. Cox

January 24, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Opinion Editor's Corner ESC 2023

What’s Going to Be Hot at ESC 2023?

Shelley Wood

August 15, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2023

Shelley Wood

March 01, 2023

News Daily News

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

L.A. McKeown

January 24, 2023

News Conference News ISET 2023

The PE Pipeline: Evidence Trickles in for Catheter-Based Therapies

Caitlin E. Cox

January 23, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Features

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

L.A. McKeown

December 02, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2022

Caitlin E. Cox

December 01, 2022

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Conference News ISC 2022

Stroke Thrombectomy Also Benefits Kids, Observational Study Shows

Todd Neale

February 16, 2022

News Conference News ISC 2022

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

Todd Neale

February 11, 2022

News Daily News

TCTMD’s Top 10 Most Popular Stories for November 2021

Shelley Wood

November 30, 2021

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

Caitlin E. Cox

October 11, 2021

News Daily News

Long-term Anticoagulation After Unprovoked VTE: New Insights

Shelley Wood

September 13, 2021

News Conference News ESC 2021

ACST-2: Carotid Stenting, Surgery Provide Similar Outcomes in Asymptomatic Patients

Todd Neale

August 29, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

Advertisement

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

January 2024 Dispatch for the CV Team

What’s Going to Be Hot at ESC 2023?

TCTMD’s Top 10 Most Popular Stories for February 2023

REVIVE Injects Fresh Data Into Surgery vs Stenting Controversy for PAD

The PE Pipeline: Evidence Trickles in for Catheter-Based Therapies

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Does BEST-CLI Settle the Surgery vs Endovascular Question for CLTI?

TCTMD’s Top 10 Most Popular Stories for November 2022

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

What’s Going to Be Hot at ESC 2022?

Stroke Thrombectomy Also Benefits Kids, Observational Study Shows

CHOICE: Intra-arterial tPA Enhances Benefit of Stroke Thrombectomy

TCTMD’s Top 10 Most Popular Stories for November 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

Long-term Anticoagulation After Unprovoked VTE: New Insights

ACST-2: Carotid Stenting, Surgery Provide Similar Outcomes in Asymptomatic Patients

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content